Efforts have been made to add other drugs to the azacitidine backbone and compare to azacytidine
monotherapy, with mixed success, and likely due to premature discontinuation and/or diose
modification of the active drugs.
References
Garcia-Manero G, Jabbour E, Borthakur G, et al. Randomized open-label phase II study of decitabine in patients
with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013; 31(20):2548-2553.
Saunthararajah Y, Sekeres M, Advani A, et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients
with myelodysplastic syndromes. J Clin Invest. 2015 Mar 2;125(3):1043-55.
Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose
azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep 28;130(13):1514-1522.
Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque
L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. Oral
cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized
crossover study. Blood. 2020 Aug 6;136(6):674-683.
F
enaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List
A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR;
International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label,
phase III study. Lancet Oncol. 2009 Mar;10(3):223-32.
L
übbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR,
Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans
PW. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk
myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III
study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS
Study Group. J Clin Oncol. 2011 May 20;29(15):1987-96.
S
ekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D,
Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ,
Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or
With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North
American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753.